

Timetable
Friday, May 25 2018

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00-09.30	S 7.1 Hot and new in transplantation: selected topics from 2017/18	S 4.9 CKD - new therapeutic approaches	S 3.1 Membranous nephropathy - the evolving story	S 6.2 Optimising clinical outcomes and technique survival	S 5.2 The non-dialysis pathway in ESRD	FC 01 Salt and related issues	FC 02 Cardiovascular complications in dialysis	FC 03 History of nephrology		
09.30-10.45	<i>Posters, coffee break and exhibition visit</i>									PACE-CME - BOEHRINGER INGELHEIM / LILLY
10.45-11.30	PL 2 Klaus Olgaard: New paradigms of the kidney - Vascular-bone axis in CKD									
11.30-11.45	<i>Break</i>									
11.45-13.15	S 0.2 - Late Breaking Clinical Trials	S 4.2 Progression of chronic kidney disease – hot issues beyond blood pressure and renin-angiotensin system	S 6.3 Optimising fluid management in PD patients	S 5.9 DOPPS - The sweet truth: Optimizing care in advanced CKD and dialysis with a focus on diabetic patients	S 3.6 Glomerular disease in the omics era	FC 04 AKI experimental	FC 05 <u>Clinical</u> nephrology 1	FC 06 CKD rehabilitation	FC 07 Clinical hypertension 1	
13.15-14.45		VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA	BAXTER HEALTHCARE	FRESENIUS MEDICAL CARE	AMGEN EUROPE	DANONE NUTRICIA RESEARCH	ASTRAZENECA PHARMACEUTICAL S LP	SANOFI- GENZYME	MSD	PACE-CME - RESVERLOGIX
15.00-16.30	S 0.4 ASN Highlights	S 3.5 Lupus and vasculitis - therapy	S 5.3 Uremic toxicity - New insights	S 8.2 A new life for sodium in Nephrology	S 1.1 Renal physiology - tubular transport	FC 08 Renal pathology 1	FC 09 Biomarkers in CKD	FC 10 Bone disease in HD	FC 11 Transplantation epidemiology	
16.30-17.00	<i>Posters, coffee break and exhibition visit</i>									
17.00-18.30	S 8.3 Diabetic nephropathy	S 5.7 Treatment of CKD-MBD	0.5 ERA-EDTA & Japanese Society of Nephrology	S 7.3 Expanding the donor pool (deceased and live donors) KPD, ABOi, machine perfusion	S 4.8 n-3 PUFA in CKD: Does it matter?	FC 12 Clinical nephrology 2	FC 13 Genetic diseases	FC 14 CKD risk and progression	FC 15 AKI clinical 1	
18.45-19.45							SIEMENS HEALTHINEERS			ZYDUS TRANS- IMMUNE (A DIVISION OF CADILA HEALTHCARE)

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00-09.30	S 8.1 Hot topics in hypertension	S 5.5 Challenges in CKD	S 4.1 Update in plasmapheresis for treating kidney diseases	S 2.2 Pediatric nephrology	S 9.2 AKI in various circumstances	FC 16 Anaemia in CKD	FC 17 Diabetes clinical	FC 18 Transplantation treatment		
09.30-10.45	<i>Poster session, coffee break and exhibition visit</i>						ASAHI KASEI MEDICAL EUROPE	OTSUKA PHARMACEUTICAL EUROPE	ERA-EDTA General Assembly	SHIRE INTERNATIONAL
10.45-11.30	PL 3 Bruce Sullenger: From the RNA world to the clinic: RNAs as drugs and drug targets									
11.30-11.45	<i>Coffee break and exhibition visit</i>									
11.45-13.15	S 4.7 CKD as a public health priority: organizational models	0.6 ERA-EDTA & Chinese Society of Nephrology	0.8 ERA-EDTA & European Society for Paediatric Nephrology	S 9.3 Renal Replacement Therapy in the Intensive Care Unit	0.1 ERA-EDTA Registry	FC 19 Glomerulonephritis 1	FC 20 CKD epidemiology	FC 21 CKD-MBD		
13.15-14.45		VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA	BAXTER HEALTHCARE	ALEXION PHARMACEUTICALS	B.BRAUN AVITUM	ASTRAZENECA PHARMACEUTICALS LP	TERUMO BCT	NXSTAGE MEDICAL	MEDICE ARZNEIMITTEL PÜTTER	AMICUS THERAPEUTICS
15.00-16.30	S 6.4 Home hemodialysis in Europe 2018	S 5.6 Cardiovascular calcifications in CKD	S 4.6 Focus on surrogate end-points in Nephrology	S 3.3 Plasma cell dyscrasias and the kidney	S 1.2 Mitochondria : critical players in kidney disorders	FC 22 Renal pathology 2	FC 23 Clinical hypertension 2	FC 24 Extracorporeal treatment	FC 25 Inflammation in CKD	
16.30-17.00	<i>Posters, coffee break and exhibition visit</i>									
17.00-18.30	S 2.1 Recent findings in ADPKD	S 5.1 Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?		S 7.2 Humoral immunity (HLA and non-HLA)	S 4.3 New biomarkers of CKD progression	FC 26 Cell biology	FC 27 Glomerulonephritis 2	FC 28 AKI Clinical 2	FC 29 Outcome in dialysis	

	Congress Hall A1	Congress Hall A2	Auditorium 10-11-12	C1-M1-2	Auditorium 15	Congress Hall A3	C1-M3	C1-M4	C1-M5	C1-M0
08.00-09.30	S 5.8 The diagnosis of Heart Failure in End Stage Kidney Disease (ESKD): a lingering dilemma	S 3.2 IgA nephropathy: from genes to therapeutic controversies	S 7.4 Post transplantation diabetes mellitus - relation to obesity and new options/challenges	S 9.1 AKI biomarkers and risk factors	0.7 ERA-EDTA & European Society of Hypertension	S 2.3 Pregnancy, CKD and hypertension	S 4.4 Interstitial fibrosis and mechanisms of CKD progression	FC 30 Nutrition in CKD	FC 31 Vascular access	FC 32 Peritoneal dialysis
09.30-09.45	<i>Break</i>									
09.45-10.30	PL 4 Marcello Tonelli: Epidemiology of kidney disease									
10.30-10.45	<i>Coffee break</i>									
10.45-12.15	S 5.4 New methods of anaemia management in CKD patients	S 7.5 Risk profiling in renal transplant patients	S 3.4 Rituximab in immune mediated glomerular diseases: one drug does not fit all	S 4.5 Controversy: too much Nephrology?	S 6.1 Lessons from International Databases (in collaboration with ISPD)	S 1.3 APOL1 impact in kidney disease	FC 33 Renal development and cystic diseases	FC 34 Acid-base balance and uric acid	FC 35 Diabetes basic research	FC 36 Paediatric nephrology
12.15-12.30	<i>Break</i>									
12.30-14.00	SS 1 Nephrology Pearls									

Fluids and electrolytes, tubular transport, physiology

Hereditary disorders, development, pregnancy, paediatric nephrology

Glomerular diseases and general clinical nephrology

Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging

End Stage Renal Disease and dialysis

Home therapies, peritoneal dialysis

Transplantation and immunology

Hypertension, diabetes, vascular diseases

Acute Kidney Injury and intensive care nephrology